新诊断多发性骨髓瘤早期治疗反应与结局
该研究评估840例新诊断多发性骨髓瘤患者(2004-2015年)早期获得快速反应对结局的影响。2周期后≥非常好的部分缓解(VGPR)率为29%,4周期后为42%,最佳反应为66%。早期反应者高危特征更多,但2或4周期时≥VGPR与<VGPR的PFS和OS无显著差异;最佳反应≥VGPR者PFS和OS改善。
要点
- 2周期后≥VGPR率为29%,4周期后为42%,最佳反应为66%。
- 2周期或4周期时≥VGPR与<VGPR者的PFS和OS无显著差异。
- 最佳反应≥VGPR者PFS和OS改善,但多因素分析中2周期后≥VGPR与PFS和OS改善无关。
核心结论
- 尽管高危疾病患者更可能获得早期反应,但快速获得深度反应本身并不影响长期结局。
研究设计与样本
- 研究纳入2004年至2015年840例新诊断多发性骨髓瘤患者,评估快速反应的影响。
主要发现
- 2周期后≥VGPR率为29%(240/840),4周期后为42%(350/840),最佳反应为66%(552/840)。
- 2周期后≥VGPR与<VGPR患者的中位PFS为28 vs 30个月(P=0.6),中位OS为78 vs 96个月(P=0.1)。
- 4周期后≥VGPR与<VGPR患者的中位PFS为31 vs 29个月,中位OS为89 vs 91个月(P=0.9)。
- 最佳反应≥VGPR与<VGPR患者的中位PFS为33 vs 22个月(P<0.001),中位OS为102 vs 77个月(P=0.003)。
- 按移植状态分层的多因素分析中,2周期后≥VGPR与PFS改善无关(移植队列HR 1.1,95%CI 0.7-1.6;非移植队列HR 1.2,95%CI 0.8-1.7),与OS改善无关(移植队列HR 1.6,95%CI 0.9-2.9;非移植队列HR 1.5,95%CI 1.0-2.4)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We evaluated the impact of achieving a rapid response in 840 newly diagnosed multiple myeloma patients from 2004 to 2015. Rates of very good partial response (VGPR) or better were 29% (240/840) after 2 cycles of treatment, 42% (350/840) after 4 cycles of treatment, and 66% (552/840) as best response. Early responders after 2 cycles of treatment had higher rates of light chain disease, anemia, renal failure, International Staging System (ISS) stage III disease, and high-risk cytogenetics, especially t(4;14), and were more likely to have received triplet therapy and undergo transplant. Median progression-free survival (PFS) and overall survival (OS) were not different among patients with ≥VGPR and <VGPR after 2 cycles (PFS, 28 vs 30 months, P = .6; OS, 78 vs 96 months, P = .1) and 4 cycles (PFS, 31 vs 29 months; OS, 89 vs 91 months, P = .9), although both were improved, with ≥VGPR as best response (PFS, 33 vs 22 months, P < .001; OS, 102 vs 77 months, P = .003). On multivariate analysis stratified by transplant status, achievement of ≥VGPR after 2 cycles was not associated with improved PFS (hazard ratio [95% confidence interval]; transplant cohort, 1.1 [0.7-1.6]; nontransplant cohort, 1.2 [0.8-1.7]) or OS (transplant cohort, 1.6 [0.9-2.9]; nontransplant cohort, 1.5 [1.0-2.4]). Covariates in the model included high-risk cytogenetics, ISS stage III, triplet therapy, creatinine ≥2 mg/dL, light chain disease, and age. Although patients with high-risk disease are more likely to achieve early response, a rapid achievement of a deep response by itself does not affect long-term outcomes.
引用
- Tandon N, Sidana S, Rajkumar SV, et al. Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma. Blood Adv. 2019. PMID: 30824418. doi:10.1182/bloodadvances.2018022806
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。